Is hip cartilage preservation realistic for my hip joint?

The decision usually comes into focus when two very different situations are compared: a 45‑year‑old with a small, well‑defined cartilage defect and otherwise “preserved joint space” on imaging may reasonably consider hip joint preservation, while a 70‑year‑old with constant groin pain and “advanced osteoarthritis” across the joint is more likely to get predictable relief from hip replacement. To avoid the brochure-style opener used elsewhere, this section starts with that real-world crossroads rather than clinic logistics.

A practical way of thinking about treatment is a stepped pathway through hip pain, moving from lower to higher commitment:

• symptom management (for example, physiotherapy and simple pain relief)
• biologic / injection support (including steroid, PRP or Arthrosamid)
• cartilage preservation / scaffold approaches (including ChondroFiller as an injectable collagen scaffold in some pathways, and osteochondral allograft surgery in selected cases)
• hip replacement when damage is advanced, or when preservation options have not held up over time.

Whether a hip joint is still “preservable” is usually judged on imaging and joint status rather than pain alone. In published hip preservation work, poorer results are reported when established osteoarthritis is present (for example, Tönnis grade 2–3), compared with more focal defects in a relatively preserved hip. Practical signals that often point towards a focal problem include scan wording such as “focal full‑thickness chondral defect” or a named area of damage on the acetabulum or femoral head, whereas phrases like “diffuse cartilage thinning”, “bone-on-bone”, “osteophytes”, or “marked joint‑space narrowing” tend to align with later‑stage arthritis where replacement becomes the more realistic endpoint.

Even when preservation is appropriate, “delay” is the honest goal. In one prospective cohort of 26 adults having hip arthroscopy for femoroacetabular impingement with acetabular lesions larger than 2 cm² treated with ChondroFiller gel, 2/26 later required total hip replacement, and those with Tönnis 2–3 osteoarthritis did poorly. In another published series of 91 hips treated with microfracture augmented with an allograft cartilage scaffold (BioCartilage) and PRP, 10/91 (10.9%) converted to total hip arthroplasty by roughly 2 years; and in a registry series of 29 young patients having femoral head osteochondral allograft, 4/29 (13.7%) converted to hip arthroplasty by around 3–4 years.

Lincolnshire Hip describes “two paths through hip pain” — preservation-style injections and, when needed, hip replacement — with assessment delivered in Lincolnshire (including Grantham and Sleaford) and a defined surgical pathway for replacement. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

How do ChondroFiller hip injections differ from steroid and PRP?

A useful way to separate these hip injections is to look at what they are trying to change in the hip joint: inflammation and pain, or the joint surface itself.

• ChondroFiller (injectable collagen scaffold): described as an ultrasound‑guided outpatient injection of an acellular type‑I collagen gel that “gels in minutes” and is intended to sit in a focal cartilage defect as a 3‑D matrix for the body’s own cells over time. In clinic language it is often framed as a “supportive” joint‑preserving option rather than a cure for hip arthritis, and any meaningful change is usually described as gradual (often 6–12 months) rather than immediate.
• Corticosteroid injection: typically used when pain is being driven by a flare of inflammation in hip osteoarthritis, aiming for symptom relief rather than rebuilding cartilage. Randomised hip osteoarthritis studies have compared steroid with hyaluronic acid and saline, reflecting its established role as a symptom‑modifying injection.
• PRP injection: generally used as a biologic injection approach aimed at influencing inflammation and healing signals; it is not a structural scaffold that “fills” a cartilage gap in the way ChondroFiller is designed to.

Patient selection is where the differences matter most. Lincolnshire Hip presents ChondroFiller as a consideration for localised wear or early arthritis—situations where imaging still suggests a relatively preserved joint rather than extensive bone‑on‑bone change. In published hip cartilage‑repair literature using ChondroFiller surgically (with follow‑up reported out to 60 months), outcomes are reported to be poorer when osteoarthritis is already established (for example Tönnis grade 2–3), which supports a cautious view about its role in more advanced arthritis.

There are no robust head‑to‑head hip trials directly comparing ChondroFiller hip injections with steroid or PRP, so decisions are usually based on the pattern on scan (focal defect vs diffuse arthritis), the aim (short‑term symptom control vs a longer‑term joint‑preservation attempt), and practicalities of downtime and cost. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

When is hip osteochondral allograft used instead of hip replacement?

For larger, localised damage in the femoral head—where a simple injection is unlikely to be enough—hip osteochondral allograft (OCA) is one of the main “joint‑surface restoration” options considered before moving straight to hip replacement. The through‑line is straightforward: OCA is used mainly in younger patients with a big, focal osteochondral defect, and in published series it often buys meaningful function for most, but around 1 in 8 to 1 in 4 still convert to hip arthroplasty within about 3–4 years.

OCA involves transplanting a matched piece of donor cartilage with its underlying bone and shaping it to fit the damaged part of the femoral head in a single operation, aiming to restore both the joint surface and the supporting subchondral bone. In a 2014 British series of 17 patients (mean age 25.9 years) treated via surgical hip dislocation, 13/17 had fair‑to‑good outcomes at a mean 41.6 months, while 1 had already progressed to hip replacement and 2 were awaiting it.

Across newer mid‑term reports, improvements in patient‑reported hip function are common (for example, mHHS 62→84 and iHOT‑12 36→78 at about 48 months in a 24‑patient series), but conversion still happens (for example 6/24 [25%] at a mean 3.8 years, and 4/29 [13.7%] in a registry cohort at roughly 3–4 years). Case‑based AVN work (for example Ficat II–III) also describes pain and function improvements with imaging evidence of graft incorporation, suggesting a potential role in delaying collapse in selected hips.

Compared with immediate hip replacement, OCA is typically positioned where the rest of the hip joint is not yet diffusely arthritic and the priority is to delay the first arthroplasty in a very young adult, accepting that OCA is technically demanding and usually limited to specialist centres. In a programme report of 33 patients, overall hip preservation was 84.8% at ≥1 year, with outcomes linked to technical factors such as graft preservation method and surface involvement. Lincolnshire Hip’s role in this pathway is to recognise when the pattern on imaging suggests a potentially “restorable” femoral head lesion and to guide appropriate discussion and referral; Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

How does recovery after hip cartilage repair compare with hip replacement?

Recovery after hip joint preservation often has two timelines running in parallel: the short-term recovery from the injection or operation itself (days to weeks), and the slower “biological” phase as cartilage or graft tissue matures (often measured in months rather than days).

ChondroFiller hip injection (ultrasound-guided, outpatient)

Clinic pathways describe ChondroFiller as an ultrasound-guided, incision-free hip joint injection with a prompt return to normal day-to-day activities. The main trade-off is that any structural effect is expected to build gradually: where it works as intended, new tissue formation within the collagen scaffold is typically described over roughly 6–12 months, rather than immediately after the injection. Driving and desk-based work are often discussed in “days” rather than “weeks” if pain settles quickly, but higher-impact activity is usually progressed more cautiously because the biological timeline is slower than the procedural downtime.

Arthroscopic hip cartilage repair (scaffold-based / microfracture-augmented)

Keyhole hip cartilage procedures tend to sit between injections and hip replacement for early disruption: mobility aids such as crutches are commonly used at first, physiotherapy is stepped up over weeks, and return to heavier loading can take months depending on defect location and size. In published hip series, longer-term outcomes are mixed rather than guaranteed: for example, a 26-patient cohort using arthroscopic ChondroFiller gel reported good/excellent outcomes in 17/21 followed to 3–5 years, while 2/26 later needed total hip replacement; outcomes were poorer with established osteoarthritis (Tönnis 2–3). In another report of 91 Outerbridge IV hips treated with microfracture plus scaffold (BioCartilage) and PRP, about 10.9% still converted to total hip arthroplasty by around 31 months.

Hip osteochondral allograft (OCA)

When a femoral head defect is reconstructed with an osteochondral allograft via surgical hip dislocation, rehabilitation is commonly more protective than after straightforward arthroscopy because both cartilage and underlying bone need to incorporate. That usually means a longer period of structured physiotherapy and a more cautious progression back to manual work or sport over “many months”, with close follow-up. Mid-term series illustrate why expectations matter: a British 17-patient report (mean follow-up 41.6 months) included 1 patient who had already progressed to hip replacement and 2 awaiting it, despite improved Harris Hip Scores overall.

Hip replacement (UK context)

NHS guidance describes total hip replacement as a major operation, typically involving a hospital stay of “a few days”, early walking with aids soon after surgery, and “several weeks” of physiotherapy, with full recovery taking “several months”. Pain relief can be more predictable earlier in the pathway than with cartilage restoration approaches, but it is a reconstructive procedure that replaces (rather than regenerates) the hip joint.

In the Lincolnshire Hip pathway, rehabilitation support is organised close to home (including local appointments in Sleaford and Grantham, and post-operative physiotherapy as part of its managed surgical pathway), which can reduce the travel burden during the most rehab-intensive weeks.

What do hip cartilage scaffold injections cost and how does Lincolnshire Hip fit?

Costs for hip cartilage scaffold injections can feel like “shopping” if they are presented as a simple price list, so it is more useful to start with what typically drives the figure up or down in 2025–2026 private care: the amount of scaffold used, whether ultrasound-guided placement and antibiotic cover are bundled, what imaging is included, and how much planned follow-up and rehabilitation is built into the package. In the UK, these ultrasound-guided scaffold injections are largely accessed privately rather than through standard NHS hip osteoarthritis pathways, which tend to progress from conservative care to hip replacement when appropriate.

Within Lincolnshire Hip’s hip-only pathway, published self-pay pricing puts ChondroFiller hip injections at about £2,995 per hip, with Arthrosamid also about £2,995 per hip, and PRP at about £1,200 (figures that can change over time). These options are positioned as joint-preserving support for selected hip joint problems, and are delivered locally via the clinic’s Lincolnshire sites listed for booking (including Grantham and Sleaford).

For wider context within the same clinical network, London Cartilage Clinic publishes ChondroFiller injection pricing from about £3,000 for one box, increasing with larger volumes (up to about £8,000 for three). It also lists all-inclusive cartilage repair surgery pricing starting at about £9,800 for knee and approximately 30% higher (≈£12,740) for non-knee joints, illustrating how quickly costs rise as treatment moves from injection support towards operative cartilage restoration.

Set against that, Lincolnshire Hip’s fixed-price private SPAIRE hip replacement package is £17,800, which is higher upfront but aims to provide a more definitive solution for advanced, diffuse arthritis. The takeaway is financial as well as clinical: preservation spend tends to make most sense while imaging still shows a hip joint with a realistic chance of being preserved, and becomes harder to justify once the problem is no longer localised.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for a hip assessment when a decision is needed between injection-based preservation and moving on to replacement.

1. [1] Osteochondral allograft transplantation in avascular necrosis of the hip. (2023). https://doi.org/10.4103/juoa.juoa_2_25 https://doi.org/10.4103/juoa.juoa_2_25